Silence Therapeutics plc (ADR)
General ticker "SLN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $244.9M (TTM average)
Silence Therapeutics plc (ADR) follows the US Stock Market performance with the rate: 38.7%.
Estimated limits based on current volatility of 5.8%: low 6.81$, high 7.64$
Factors to consider:
- Total employees count: 116 as of 2024
- Top business risk factors: Third-party risks, Regulatory and compliance, Cybersecurity threats, Manufacturing disruptions, Strategic risks and growth management
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.34$, 10.19$]
- 2026-12-31 to 2027-12-31 estimated range: [3.69$, 8.86$]
Short-term SLN quotes
Long-term SLN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £25.38MM | £43.26MM | £0.56MM |
| Operating Expenses | £74.98MM | £106.58MM | £90.31MM |
| Operating Income | £-49.60MM | £-63.32MM | £-89.75MM |
| Non-Operating Income | £-0.71MM | £18.86MM | £1.15MM |
| Interest Expense | £0.03MM | £0.00MM | £0.00MM |
| R&D Expense | £44.02MM | £67.88MM | £67.75MM |
| Income(Loss) | £-50.31MM | £-44.46MM | £-88.60MM |
| Taxes | £0.00MM | £0.84MM | £0.01MM |
| Profit(Loss)* | £-43.27MM | £-54.43MM | £-88.61MM |
| Stockholders Equity | £21.99MM | £134.02MM | £46.24MM |
| Assets | £119.45MM | £202.63MM | £97.55MM |
| Operating Cash Flow | £-39.35MM | £-67.64MM | £-46.32MM |
| Capital expenditure | £0.04MM | £0.21MM | £0.06MM |
| Investing Cash Flow | £16.43MM | £-21.97MM | £-35.70MM |
| Financing Cash Flow | £25.16MM | £142.09MM | £0.01MM |
| Earnings Per Share** | £-3.50 | £-3.53 | £-1.88 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.